Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone
Tue, 15/09/2020 - 00:00
0 min
Download related document
Select rating
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 1/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 2/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 3/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 4/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 5/5
No votes yet
Related
ROVI informs on the evolution of the investigation of particulate matter having...
Following the public relevant information published on 26 of August 2021 with registered number 11377, Laboratorios Farmacéuticos ROVI, S.A...
2 min
29/08/2021
ROVI informs on the evolution of the investigation of particulate matter having...
Following the public relevant information published on 26 of August 2021 with registered number 11377, Laboratorios Farmacéuticos ROVI, S.A...
2 min
29/08/2021
ROVI informs on the notification of particulate matter having been seen in...
Laboratorios Farmacéuticos ROVI, S.A. (ROVI), in compliance with the information duties set out in article 227 of the Revised Text of the...
1 min
26/08/2021
See More
Email
Facebook
Twitter
LinkedIn